Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +5 vs. previous quarter
- 32
- 13F valueReported value at the end of Q2 2026
- $9.88M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CING, Q2 2026
No superinvestor reported holding CING at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cingulate Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2026 (view filing)7:02 PM ET | Feb 13 | 115 daysLate | Hargroves Thomas JeffreyDirector | PPurchase | +97.3K | $5.04 | +$490.3K | +50,664.6%97.5K after | |
| Jun 8, 2026 (view filing)7:02 PM ET | Feb 13 | 115 daysLate | Hargroves Thomas JeffreyDirector | PPurchase | +77.8K | $0.10 | +$7.78K | –77.8K after | Derivative |
| Feb 10, 2026 (view filing)7:00 PM ET | Feb 6 | 4 days | Werth Peter J.Director | PPurchase | +19.5K | $5.04 | +$98.1K | +19.9%117.4K after | |
| Feb 10, 2026 (view filing)7:00 PM ET | Feb 6 | 4 days | Werth Peter J.Director | PPurchase | +15.6K | $0.10 | +$1.56K | –15.6K after | Derivative |
| Feb 10, 2026 (view filing)7:00 PM ET | Feb 6 | 4 days | Callahan Jennifer L.SVP and CFO | PPurchase | +4.86K | $5.04 | +$24.5K | +2,494.4%5.06K after | |
| Feb 10, 2026 (view filing)7:00 PM ET | Feb 6 | 4 days | Callahan Jennifer L.SVP and CFO | PPurchase | +3.89K | $0.10 | +$389.1 | –3.89K after | Derivative |
| Feb 10, 2026 (view filing)7:00 PM ET | Feb 6 | 4 days | Schaffer Shane J.Chief Executive Officer | PPurchase | +6.81K | $5.04 | +$34.3K | +202.3%10.2K after | |
| Feb 10, 2026 (view filing)7:00 PM ET | Feb 6 | 4 days | Schaffer Shane J.Chief Executive Officer | PPurchase | +5.45K | $0.10 | +$544.7 | –5.45K after | Derivative |
| Feb 10, 2026 (view filing)7:00 PM ET | Feb 6 | 4 days | Brams MatthewEVP and Chief Medical Officer | PPurchase | +1.95K | $5.04 | +$9.81K | +71.8%4.66K after | |
| Feb 10, 2026 (view filing)7:00 PM ET | Feb 6 | 4 days | Brams MatthewEVP and Chief Medical Officer | PPurchase | +1.56K | $0.10 | +$155.6 | –1.56K after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Cingulate Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 570,873 | $3.12M | 0.00% | +261,906+84.8% | Added |
| Raymond James Financial Inc | 166,898 | $912.9K | 0.00% | +166,898 | New |
| Chicago Partners Investment Group LLC | 188,429 | $912.0K | 0.02% | +169,679+905.0% | Added |
| Kestra Advisory Services, LLC | 151,500 | $828.7K | 0.00% | +11,500+8.2% | Added |
| Geode Capital Management, LLC | 144,636 | $791.4K | 0.00% | +43,263+42.7% | Added |
| Renaissance Technologies LLC | 127,500 | $697.4K | 0.00% | +95,612+299.8% | Added |
| Vanguard Fiduciary Trust Co | 79,160 | $433.0K | 0.00% | +29,086+58.1% | Added |
| BlackRock, Inc. | 53,130 | $290.6K | 0.00% | +29,861+128.3% | Added |
| BCV Asset Management Inc. | 51,200 | $272.9K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 47,888 | $261.9K | 0.00% | +20,300+73.6% | Added |